

# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Orbifloxacin Solid Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.

Menuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### 2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Reproductive toxicity : Category 2

**GHS** label elements

Hazard pictograms :

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of

the skin.

May form explosive dust-air mixture during processing, han-

dling or other means.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Orbifloxacin	113617-63-3	>= 3 - < 10	-
Magnesium stearate	557-04-0	>= 1 - < 10	2-611

#### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

: Suspected of damaging the unborn child.

and effects, both acute and delayed

Protection of first-aiders

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,



# **Orbifloxacin Solid Formulation**

SDS Number: Date of last issue: 2024/04/06 Version Revision Date: 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Avoid release to the environment. **Environmental precautions** 

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are re-



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

leased into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling

: Use only with adequate ventilation.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact Hygiene measures

Oxidizing agents

: If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

**Storage** 

Conditions for safe storage : Keep in properly labelled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

# Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available



# **Orbifloxacin Solid Formulation**

Version SDS Number: Date of last issue: 2024/04/06 **Revision Date:** 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Melting point/freezing point No data available

Boiling point, initial boiling point and boiling range

No data available

Flammability (solid, gas) May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Up- : No data available

per flammability limit

Lower explosion limit / Lower flammability limit No data available

Flash point Not applicable

Decomposition temperature No data available

pΗ No data available

**Evaporation rate** No data available

Auto-ignition temperature No data available

Viscosity

Viscosity, kinematic No data available

Solubility(ies)

No data available Water solubility

Partition coefficient: n-

octanol/water

No data available

Vapour pressure No data available

Density and / or relative density

Relative density No data available

Density No data available

Relative vapour density No data available

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Particle characteristics

Particle size : No data available

## 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

#### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation Skin contact

Ingestion Eye contact

#### **Acute toxicity**

Not classified based on available information.

#### **Components:**

#### Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg Symptoms: Vomiting

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 200 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg Application Route: Intramuscular



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

LD50 (Rat): 233 mg/kg

Application Route: Intravenous

LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

#### Skin corrosion/irritation

Not classified based on available information.

#### **Components:**

# Orbifloxacin:

Species: RabbitMethod: Draize TestResult: No skin irritation

## Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

#### Serious eye damage/eye irritation

Not classified based on available information.

## **Components:**

## Orbifloxacin:

Species : Rabbit

Result : Mild eye irritation
Method : Draize Test

## Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

## Respiratory sensitisation

Not classified based on available information.

#### **Components:**

#### Orbifloxacin:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

#### Magnesium stearate:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

## Germ cell mutagenicity

Not classified based on available information.

## Components:

## Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: equivocal

Test Type: Mouse Lymphoma

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow

Application Route: Intraperitoneal injection

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral

Result: negative



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Germ cell mutagenicity -

Assessment

: Weight of evidence does not support classification as a germ

cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

## Carcinogenicity

Not classified based on available information.

## **Components:**

#### Orbifloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

# Reproductive toxicity

Suspected of damaging the unborn child.

### **Components:**

#### Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

**Application Route: Oral** 

General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body

weight

Result: No adverse effects

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high ma-

ternally toxic doses

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight

Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal

body weight gain

Test Type: Development

Species: Dog

Application Route: Oral

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Effects on postnatal development, Skeletal malfor-

mations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

## Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

## Repeated dose toxicity

## **Components:**

#### Orbifloxacin:



# **Orbifloxacin Solid Formulation**

Version SDS Number: Date of last issue: 2024/04/06 Revision Date: 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Species Rat NOAEL 20 mg/kg LOAEL
Application Route
Exposure time
Target Organs : 80 mg/kg : Oral 3 Months

Target Organs Testis, Liver, Kidney, spleen

**Species** Mouse NOAEL 80 mg/kg LOAEL 250 mg/kg Application Route Oral Exposure time 3 Months

Species Juvenile dog NOAEL 50 mg/kg LOAEL 250 mg/kg LOAEL
Application Route
Exposure time
Target Organs
Symptoms
Remarks : Oral : 14 Days : Heart, Bone

: Gastrointestinal disturbance

: mortality observed Remarks

Species : Juvenile dog NOAEL : 2 mg/kg LOAEL
Application Route
Exposure time
Target Organs
Remarks 3 mg/kg Oral 90 Days Bone

Remarks No significant adverse effects were reported

Species NOAEL 37.5 mg/kg Application Route : Oral Exposure time : 30 Days

**Species** : Cat NOAEL : 7.5 mg/kg LOAEL : 22.5 mg/kg Application Route : Oral Exposure time : 1 Months

Gastrointestinal disturbance Symptoms

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg : Ingestion : 90 Days Application Route Exposure time

Remarks : Based on data from similar materials

**Aspiration toxicity** 

Not classified based on available information.



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

## **Experience with human exposure**

# **Components:**

#### Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal

disturbance, liver function change, anaphylaxis, Rash

Remarks: May cause photosensitisation.

## 12. ECOLOGICAL INFORMATION

## **Ecotoxicity**

### **Components:**

# Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/I

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

ma/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

## Persistence and degradability

**Components:** 

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

**Bioaccumulative potential** 

**Components:** 

Magnesium stearate:

Partition coefficient: n-

log Pow: > 4

octanol/water

Mobility in soil
No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

## 13. DISPOSAL CONSIDERATIONS

**Disposal methods** 

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### 14. TRANSPORT INFORMATION

## International Regulations

**UNRTDG** 

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

**IATA-DGR** 

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Labels : Not applicable Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen-

ger aircraft)

Not applicable

**IMDG-Code** 

**UN** number Not applicable Not applicable Proper shipping name Not applicable Class Not applicable Subsidiary risk Packing group Not applicable Labels Not applicable **EmS Code** Not applicable Marine pollutant Not applicable

# Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **National Regulations**

Refer to section 15 for specific national regulation.

### Special precautions for user

Not applicable

## 15. REGULATORY INFORMATION

## **Related Regulations**

#### **Fire Service Law**

Not applicable to dangerous materials / designated flammables.

#### **Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

## **Industrial Safety and Health Law**

## **Harmful Substances Prohibited from Manufacture**

Not applicable

#### Harmful Substances Required Permission for Manufacture

Not applicable

#### **Substances Prevented From Impairment of Health**

Not applicable

# Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

# Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

# **Substances Subject to be Notified Names**

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
Magnesium stearate	>=1 - <10	-

# Substances Subject to be Indicated Names

Article 57 (Enforcement Order Article 18)

Chemical name	Remarks
Magnesium stearate	-

## Skin and Eye Damage Substances for PPE Requirements (ISHL MO Art. 594-2)

Not applicable

# Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

### Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

## **Ordinance on Prevention of Lead Poisoning**

Not applicable

## Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

## **Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

# Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

### **Poisonous and Deleterious Substances Control Law**

Not applicable

# Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

## **High Pressure Gas Safety Act**

Not applicable

# **Explosive Control Law**

Not applicable

### **Vessel Safety Law**

Not regulated as a dangerous good

## **Aviation Law**

Not regulated as a dangerous good

## Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

Pack transportation : Not classified as marine pollutant

## **Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

## Waste Disposal and Public Cleansing Law

Industrial waste

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

#### **Further information**

Sources of key data used to : compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Con-



# **Orbifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 801084-00019 Date of first issue: 2016/07/15

centration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: Nch - Chilean Norm: NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN